Edition:
United Kingdom

AveXis Inc (AVXS.OQ)

AVXS.OQ on NASDAQ Stock Exchange Global Select Market

98.92USD
15 Dec 2017
Change (% chg)

$-0.02 (-0.02%)
Prev Close
$98.94
Open
$99.21
Day's High
$102.15
Day's Low
$96.75
Volume
720,963
Avg. Vol
159,429
52-wk High
$108.27
52-wk Low
$45.37

Chart for

About

AveXis, Inc. is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company's product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for... (more)

Overall

Beta: --
Market Cap(Mil.): $3,310.99
Shares Outstanding(Mil.): 31.93
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Avexis plans to initiate Phase 1 trial in SMA Type 2

* AVEXIS ANNOUNCES PLAN TO INITIATE PHASE 1 TRIAL IN SMA TYPE 2 UTILIZING INTRATHECAL DELIVERY OF AVXS-101 Source text for Eikon: Further company coverage:

13 Dec 2017

BRIEF-Avexis posts Q3 loss per share $1.52

* Avexis reports third quarter 2017 financial and operating results

09 Nov 2017

BRIEF-Avexis Inc CFO Thomas Dee resigns

* Avexis Inc - ‍on October 14 Thomas J. Dee resigned as senior vice president, chief financial officer - SEC filing

19 Oct 2017

BRIEF-AveXis to report top-line data from phase 1 clinical trial of AVXS-101

* AveXis to report top-line data from the Phase 1 clinical trial of AVXS-101 in SMA Type 1 at the International Annual Congress Of The World Muscle Society

03 Oct 2017

BRIEF-Avexis to initiate pivotal trial of AVXS-101 in SMA type 1

* Avexis announces plan to initiate pivotal trial of AVXS-101 in SMA type 1 using product from new GMP commercial process

29 Sep 2017

BRIEF-AveXis reports Q2 loss per share $2.07

* AveXis reports second quarter 2017 financial and operating results

10 Aug 2017

Earnings vs. Estimates